Overview

A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

Status:
Not yet recruiting

Trial end date:
2023-02-15

Target enrollment:

Participant gender:

Summary

This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Lannett Company, Inc.

Collaborator:

Parexel

Treatments:

Insulin Glargine